Thomas Marbury

Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment

A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment

Pharmacokinetics of Gepotidacin in Renal Impairment

Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics

Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects

Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment

Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment

Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment

Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function